Melanoma Tumor Board Conference (MELCO)

1. Discuss Signal Transduction Pathway Targeted Therapy and strategies to overcome Inhibitor Refractory Melanoma.
2. Interpret genetic mutations and molecular targets involving Melanoma progression, metastasis and drug resistant therapy.
3. Identify subtypes of cutaneous melanomas and uveal melanomas and apply appropriate management strategies, according to disease stage and tumor mutation status.

This is a closed, invitation only series.  If you are interested in attending this series, contact Chris Castro - Activity Coordinator - at [email protected]

View the accessibility policy for The University of Texas M.D Anderson Cancer Center.

The University of Texas MD Anderson Cancer Center complies with all requirements of the identified accrediting body  (ACCME, ANCC, ACPE). Disclosure of speakers, faculty members, planning committee members and their commercial relationships will be shared with learners prior to the educational activity.

Mitigation of Relevant Financial Relationships

Faculty Member Information

Role in activity

Name of Ineligible Company(s) / Nature of Relationship(s)

Jeffrey Gershenwald, MD
Professor
The University of Texas MD Anderson Cancer Center

Activity Co-Director

Consulting Fee-Merck Sharp & Dohme Corp. (any division)|Consulting Fee-Regeneron Pharmaceuticals, Inc. (Relationship has ended)

B. Ashleigh Guadagnolo, MD, MPH
Professor
MD Anderson Cancer Center

Activity Co-Director, Faculty

Nothing to disclose

Rodabe N. Amaria, MD
Associate Professor, Melanoma Medical Oncology
The University of Texas MD Anderson Cancer Center

Activity Director

Grant or research support-Novartis Pharmaceuticals Corporation|Grant or research support-Merck Sharp & Dohme Corp. (any division)|Grant or research support-Bristol-Myers Squibb Company|Grant or research support-Iovance|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Novartis Pharmaceuticals Corporation|Grant or research support-Obsidian|Grant or research support-OnKure|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Bristol-Myers Squibb Company|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Iovance|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Nektar (Relationship has ended)

Ryan Goepfert, MD
MD Anderson

Other Planning Committee Member

Nothing to disclose

Natalie J Jackson, FNP-C, APRN
APRN
UT MD Anderson Cancer Center

Other Planning Committee Member

Nothing to disclose

Jennifer McQuade, MD
Assistant Professor
MD Anderson Cancer Center

Other Planning Committee Member

Honoraria-Merck Sharp & Dohme Corp. (any division)

Madhavi Patnana, MD
Professor
MD Anderson Cancer Center

Other Planning Committee Member

Nothing to disclose

Victor G Prieto, MD, PhD, USCAP, ASDP, ISDP, CAP, ASCP
Chair and Professor
UT - MD Anderson Cancer Center

Other Planning Committee Member

Consulting Fee-Myriad|Consulting Fee-Orlucent|Consulting Fee-Castle Biosciences, Inc.